Ashley Davis
Family · Humble, TXNPI 1134778624
Payments from drug & device makers
Across 330 payments — averaging $16.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Boston Scientific$663
- AbbVie$550
- Sanofi-aventis U.S. LLC$514
- Dexcom, Inc.$490
- Lilly USA, LLC$376
- plus $2K from 30 others
What the payments were for
- Food & beverage$5,486100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 63 | $1,042 |
| Boston Scientific | 31 | $663 |
| AbbVie | 38 | $550 |
| Sanofi-aventis U.S. LLC | 32 | $514 |
| Dexcom, Inc. | 47 | $490 |
| Lilly USA, LLC | 21 | $376 |
| Bayer | 19 | $325 |
| AstraZeneca(2 entities) | 13 | $232 |
| Exact Sciences | 10 | $185 |
| Radius Health, Inc. | 8 | $167 |
| Madrigal Pharmaceuticals | 3 | $94 |
| Medtronic | 3 | $80 |
| Corcept Therapeutics | 4 | $76 |
| GSK | 3 | $61 |
| Esperion Therapeutics, Inc. | 3 | $57 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $54 |
| Boehringer Ingelheim | 3 | $47 |
| Amgen(2 entities) | 2 | $43 |
| Xeris Pharmaceuticals, Inc. | 2 | $42 |
| Axsome Therapeutics, Inc. | 2 | $42 |
| Tandem Diabetes Care, Inc. | 3 | $40 |
| Neurocrine Biosciences, Inc. | 1 | $34 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $29 |
| Phathom Pharmaceuticals, Inc. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $22 |
| Ascendis Pharma Endocrinology Inc | 1 | $21 |
| Ascensia Diabetes Care US Inc. | 1 | $20 |
| Sequel Med Tech, LLC | 1 | $18 |
| Tolmar, Inc. | 1 | $17 |
| Acella Pharmaceuticals, LLC | 1 | $16 |
| BETA Bionics, Inc. | 2 | $16 |
| Cequr Corporation | 2 | $15 |
| Kyowa Kirin, Inc. | 1 | $14 |
| Merck | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACQUIRE$100
How this compares
$5,486 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 284 | $471,047 |
| MounjaroTirzepatide | 200 | $308,801 |
| JardianceEmpagliflozin | 161 | $177,285 |
| FarxigaDapagliflozin Propanediol | 63 | $58,589 |
| RybelsusSemaglutide | 23 | $47,117 |
| TrulicityDulaglutide | 25 | $42,408 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 33 | $38,142 |
| ProliaDenosumab | 20 | $33,879 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $23,458 |
| Xigduo XrDapaglifloz Propaned/Metformin | 23 | $18,336 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $17,683 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $17,070 |
| Tresiba Flextouch U-100Insulin Degludec | 23 | $16,326 |
| JanuviaSitagliptin Phosphate | 11 | $13,470 |
| VascepaIcosapent Ethyl | 11 | $8,152 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $1,042 | $523,732322 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $376 | $356,824239 claims |
| Boehringer IngelheimJardiance | $47 | $177,285161 claims |
| AstraZenecaFarxiga | $232 | $58,58963 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $514 | $38,14233 claims |
| AmgenProlia | $43 | $33,87920 claims |
| MerckJanuvia | $14 | $13,47011 claims |
| AbbVieSynthroid, Armour Thyroid | $550 | $7,70087 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 15,456 family providers in Texas.
Other family in Humble
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.